Thruvision Group secures financial future with equity raise, ends strategic review

Thruvision Group PLC has secured its immediate financial future by raising at least £2.5 million in new capital, providing a 12-month cash runway for working capital and growth investments, and concluding its strategic review to remain a standalone entity. This follows a recent £1 million contract win, which boosted Q1 FY2026 order intake by 143% year-over-year. While the equity raise, priced at 1p per share, represents significant dilution (approximately 61% of enlarged capital), it addresses prior liquidity concerns and positions the company to target cash flow break-even by FY2027 based on £10 million in annual revenue.

Analysis

Thruvision Group PLC has decisively addressed its near-term liquidity crisis by securing at least £2.5 million in new capital, which it states will provide a cash runway for at least 12 months. This fundraising, which includes a notable £380,000 contribution from company directors, effectively removes the immediate risk of insolvency that was flagged last month. The capital injection is priced at 1p per share and results in significant shareholder dilution, with the new shares representing approximately 61% of the enlarged capital base. Concurrently, the company concluded its strategic review, opting to remain a standalone entity, thereby removing the uncertainty of a potential sale. This financial restructuring is supported by positive operational momentum, evidenced by a new £1 million contract that contributed to a 143% year-over-year increase in Q1 FY2026 order intake, totaling £2.3 million. Management has set a clear forward target of achieving cash flow break-even during FY2027, contingent upon reaching £10 million in annual revenue.

Key Decisions for Investors

• With the immediate solvency risk removed, the investment thesis now pivots entirely to operational execution, requiring close scrutiny of the company's ability to convert its new funding into sustainable revenue growth towards its £10 million break-even target.
• Investors should monitor quarterly order intake and contract wins as the primary forward-looking indicators, as the strong 143% growth in Q1 must be sustained to validate the company's standalone growth strategy.
• While the director participation in the raise is a positive signal, existing shareholders must factor in the severe 61% dilution, whereas new investors may see the 1p placement price as a reset valuation floor for a company with a now-secured 12-month operational runway.